Sanofi shares lead the CAC 40, up 20% over one month against the trend
The pharmaceutical company is resisting the nervousness shaking stock markets after the correction in technology stocks. The stock stands out from a Parisian market trending lower, following the European authorization of a new vaccine.
A lead on the Parisian market confirmed by a sharp monthly rebound
Sanofi shares gain 1.65% to €85.17 during the session, while the CAC 40 falls 1.32% and the SBF 120 drops 1.38%. The stock holds first place in the index, ahead of Danone (+1.42%), while STMicroelectronics (-6.55%) loses the most ground.
The session follows a 3.19% decline over the week, but the stock remains up nearly 20% over one month and stays above its moving averages: the 200-day moving average (MM200) is at €77.03, a gap of 10.57% from the share price.
The RSI at 62 does not indicate excessive tension. The €88.32 resistance remains the closely watched upper level, while the 20-day moving average (MM20), at €82.96, sits 2.66% below the share price.
The European authorization of VaxRabeo, a new rabies vaccine, adds to the context
The European Commission has granted the first marketing authorization for VaxRabeo, the new rabies vaccine, announced by Sanofi on November 19. It covers pre-exposure and post-exposure prophylaxis for all age groups, and follows the positive opinion issued on September 17 by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
The stock had nevertheless declined the previous day despite this announcement, which makes the session's performance all the more notable.
In a context of tension in artificial intelligence-related stocks, with the VIX at 29.47, the share is moving against the American indices, which closed Thursday down about 2%. According to the consensus of the analysts surveyed, the stock trades at about 9.6 times earnings for the current fiscal year.